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THE induction of sarcomas at the site of injection of iron-dextran, of otlher
preparations of iron, and of other metal-carbohydrate complexes in rats, mice,
hamsters and rabbits is well documented (Richmond, 1957, 1959, 1960; Haddow
and Horning, 1960; Golberg, Martin and Smith, 1960 ; Lundin, 1961 ; Haddow.
Dukes and Mitchley, 1961; Haddow, Roe and Mitchley, 1964; Haddow and
Roe, 1964; Roe, Haddow, Dukes and Mitchley, 1964) and has been considered
in recent review articles (Roe and Lancaster, 1964; Roe, 1965).
The iron sorbitol-citric acid complex marketed under the name of " Jectofer'
has hitherto received less attention from the point of view of carcinogenicitv.
Lundin (1961) reported an experiment in which male or female Sprague-Dawley
rats were given repeated injections of Jectofer. The rats were injected twice
weekly with Jectofer at a rate of 0 05 ml. per injection for each 50 g. of body
weight. In this way each rat received on average a total of 255 mg. of iron over
the 4 month period. Allinjections were made intramuscularly into the right thigh.
Thirty-eight animals were kept under observation from the 38th to the 68th
week of the experiment. Amongst these, one rat developed a benign fibroma at
the injection site. Comparable groups of rats injected similarly with iroin-
dextran (Imferon) or Ferrigen (a high molecular weight iron-carbohydrate complex
marketed by Astra Chemicals) developed numerous injection-site tumours, the
first appearing around the 40th week. The tumour response was more marked
in the case of Imferon than in that of Ferrigen. Rats injected with either Im-
feron or Ferrigen according to the same schedule, but with twice as much of each
compound developed tumours in even higher incidence and after a shorter meain
latent interval. Because ofsystemic toxicity, Lundin was unable to give Jectofer
at the higher dose level.
Fielding (1962) tested Jectofer for carcinogenicity in mice, including in the
same experiment groups treated with iron-dextran (Imferon) and iron-dextrin
(Astrafer). All three groups were injected once weekly, subcutaneously in the
left flank with the iron preparation such that a dose of 1 mg. iron was given. In
the cases of Jectofer and Imferon this entailed a dose volume of 0 02 ml., but in
the case of Astrafer, the volume was 0 05 ml. In all groups injections were con-
tinued for 28 to 30 weeks and the experiment was terminated after 17 months.
No injection-site tumours were seen in 28 Jectofer-treated mice which lived for
12 months or more, whereas 2 out of 17 mice developed tumours in response to
iron-dextran and 3 out of 12 to iron-dextrin.
The experiment reported in the present paper represents a third attempt to
induce tumours by the injection of Jectofer. Once again, as a positive control,
animals (rats) were injected with iron-dextran (Imferon). Attention was paid,F. J. C. ROE AND A. HADDOW
however, to the incidence not only of injection-site tumours but of tumours of
all sites.
MATERIALS AND METHODS
Rats.-Forty-eight male rats of the Chester Beatty stock Wistar strain were
used for the experiment. At 4 weeks of age they were divided randomly into
2 groups of 24 and thereafter housed in metal cages, 8 to a cage. Throughout
the experiment they were fed on a cubed diet, Diet 86, obtained from Messrs.
Dixon & Sons ofWare, Herts. (see Roe et al., 1964, for further details) and water
was given ad libitum.
Iron preparations.-Jectofer (iron-sorbitol citric acid) was obtained from
Astra-Hewlett Ltd., and Imferon (iron-dextran) from Bengers Ltd. (now Fison's
Pharmaceuticals Division).
Both preparations contain 50 mg. iron in each millilitre.
Experimental details
It was planned to inject both preparations at the rate of 1 mg. per 50 g. body
weight, subcutaneously, in the right flank at twice weekly intervals beginning
when the rats were 4 weeks old. However, the Jectofer-treated animals became
irritable and unwell for periods of 2-6 weeks at three points during the experi-
ment. Injections were suspended during these periods in both the Jectofer-
treated and Imferon-treated groups. Details of the course of injections for both
groups are as follows: A total of 79 injections were given over a period of 52
weeks. Injections were suspended for 6 weeks from the 30th to 36th week, for
5 weeks from the 38th to 43rd week, and for 2 weeks from the 47th to 49th week.
The average total Fe given to both groups of rats was 830 mg.
RESULTS
Body weight
All animals were weighed once weekly. At the start of the experiment rats
in both groups weighed on average 130 g. They put on weight at a rate of ap-
proximately 5 g. per day for 8 weeks to reach an average weight of just over
400 g. Thereafter the growth slowed to between 1 and 2 g. per week and ceased
altogether at 43 weeks (i.e. when the rats were 47 weeks old). The growth curves
for the Imferon-treated and Jectofer-treated animals were almost identical up
to the 24th week of the experiment. During the period from the 24th to 30th
weeks the Jectofer-treated rats fell behind the Imferon-treated animals in average
body weight, the difference increasing to 30 g. by the 30th week. At this time
treatment was stopped in both because of the irritability and poor condition of
the Jectofer-treated rats. During the next 6 weeks the latter put on more weight
than the former and, by the 36th week, the mean weight in both groups was
identical. Thereafter the weight curves remained similar for the two groups.
Clinical and post mortem examination
All animals were examined weekly for the presence of tumours at the site of
injection in the right flank or at other sites. Animals with large tumours, and
sick animals, were killed and examined post mortem. Autopsy examination was
ofa uniform standard for both groups ofrats and included a thorough examination
of skin and subcutaneous tissues, lymph nodes, salivary glands, thoracic and
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abdominal organs and palpation of skeleton. The contents of the cranium were
not examined. Tissue from the injection site, tumours and other lesions seen
during macroscopic examination were sectioned and examined microscopically.
The induction of tumours at the site ofinjection
Table I provides details of the development of injection-site tumours. The
incidence was lower than expected in the Imferon-treated rats. Only 3 sarcomas
appeared among the 24 rats, 19 ofwhichlivedfor more than a year. No injection-
site tumours were seen among the Jectofer-treated animals of which, again,
19 lived for more than 12 months.
No. of animals
alive at 12
Treatment months
Jectofer
Imferon
fWith
sarcor
19 Withc
Lsarco]
f9With
I sarcor
19g Withc
tsarcor
TABLE I.-Injectton-site Sarcomata
Deaths with and without injection-site sarcomata
between 12 and 25 months ~~~~~~~~~~~~~~~-A
12- 13- 14- 15- 16- 17- 18- 19- 20- 21- 22-23- 24-
Months 13 14 15 16 17 18 19 20 21 22 23 24 25
na
)Ut . 1 1 1 2 1 2 5 3 1 2
ma
ma
)Ut
ma
- 2
1 1 3 2
-1 _
4 1 1 1 2-
No injection-site tumours arose in the animals which died before the 12th
month in either group.
Tumours at sites other than the site of injection
Table II shows the incidence of tumours other than injection-site sarcomas
in the two groups. Six ofthe Jectofer-treated rats developed neoplasms, whereas
only one of the Imferon-treated animals did so. All 6 tumours were of different
types andonly 2 ofthem, onelymphoma and onelymphosarcoma, were malignant.
Only one benign tumour was seen in the Imferon-treated animals. In none of
Treatment
TABLE II.-Neoplasms Other than Injection-site Sarcomas
Deaths with and without neoplasm
between 12 and 25 months
No. of , A
rats alive at 12- 13- 14- 15- 16- 17- 18- 19- 20- 21- 22- 23- 24-
12 months Months 13 14 15 16 17 18 19 20 21 22 23 24 25
rWith . 1(A) - - - - 1(B) 1(C) - 1(D) - - -2(E)
I neoplasm
Jectofer . . 19 ithout
tneoplasm
With
neoplasm
Imferon . . 197 Without
tneoplasm
1 1 2 1 1 4 3
-- (F) - - -
1 1 5 1 - 4 1 2 2 --
A Lymphosarcoma arising in retroperitoneal tissues.
B Soft fibroma arising in subcutaneous tissues remote from the site of injection.
c Tubular adenoma of renal cortex.
D Benign papilloma arising in renal pelvis.
E One rat had a small parenchymal cell hepatoma, and the other a localised lymphosarcoma.
F Adenomatous polyp arising in glandular part of stomach.
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the animals which died before the 12th month in either group was any neoplasm
seen.
DISCUSSION
Iron sorbitol-citric acid (Jectofer) injected repeatedly, always at the same site,
in doses not far short of the maximum tolerated, failed to induce injection-site
sarcomas. Iron-dextran injected in comparable doses gave rise to 3 sarcomas
among 24 rats, a surprisingly low yield in the light of the previous experience.
This lack of local carcinogenic effect on the part of Jectofer may be related to
the fact that it is more rapidly absorbed than Imferon from the site of injection
(Lindvall and Andersson, 1961; Wetherley-Mein et al., 1962). The fact that
more tumours of sites other than the injection-site were seen in the Jectofer-
treated rats than in the Imferon-treated rats, is difficult to assess. On the one
hand it is not unreasonable to expect that Jectofer, once it has got clear of the
injection site, will find its way to all other tissues. Thus, if it has a carcinogenic
effect this may be manifest at a variety of sites. On the other hand, this is not
what normally happens, certainly in the case of the more potent carcinogens.
Particular tissues or organs usually prove more susceptible than others to sys-
temically administered carcinogens and thus become favoured targets for its
action. In the present case, therefore, it would not be justifiable to attribute
the variety of tumours, most of them benign, in the Jectofer-treated animals
to the treatment they received.
On a body weight basis the doses of both iron preparations in the present
experiment were high compared with those used clinically. At these high dose
levels Jectofer exhibited both local and systemic toxicity, whereas Imferon did
not. Scott (1963) reported transient local reactions in only 2 out of 80 patients
treated with Jectofer. She saw general toxic manifestations more frequently,
especially in patients receiving oral iron at the same time, and in patients suffering
from folic acid deficiency anaemia. Most of these manifestations, e.g. headache,
vomiting and nervous symptoms, would only be detected in rats if they were
severe enough to give rise to poor condition or weight loss. Pyelitis was a fre-
quent complication in Jectofer-treated patients who became folic acid deficient
and Scott (1963) suggested that Jectofer may have a pyrogen-like effect. On
the other hand, a direct irritant effect on the kidney by high concentration of
Jectofer is a possible explanation, since 30 per cent of an intramuscular dose is
excreted, unchanged, in the urine (Andersson, 1961). Untreated rats of the
strain used in the present experiment have a high incidence of chronic interstitial
nephritis. There was no indication that renal disease was more prevalent, or
more severe, in the Jectofer than in the Imferon-treated animals.
SUMMARY
1. No injection-site tumours were seen in 24 male Chester Beatty Wistar rats
injected repeatedly at the same site in the subcutaneous tissues of the right flank
with iron sorbitol-citric acid (Jectofer). Injections of 1.0 ml. per kg. were given
at twice weekly intervals over a period of 52 weeks, with three treatment-free
intervals because of toxic effects.
2. Three injection-site tumours developed among 24 rats treated similarly
with iron-dextran (Imferon). No toxic effects were encountered in this case.
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3. The incidence of tumours at sites other than the injection site was higher
in the case of the Jectofer-treated rats (6 out of 24 rats) than in the case of the
Imferon-treated rats (1 out of 24 rats). It is doubtful, however, whether any of
these non-injection-site tumours can be attributed to treatment.
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